Cardiac allograft vasculopathy: A review

Canadian Journal of Surgery

Volumn 48, Issue 4, 2005, Pages 319-327

  Ramzy, Danny ^a   Rao, Vivek ^a,c   Brahm, Julie ^a   Miriuka, Santiago ^b   Delgado, Diego ^b   Ross, Heather J ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; CARDIAC ALLOGRAFT VASCULOPATHY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; EARLY DIAGNOSIS; ENDOTHELIUM INJURY; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INTRAVASCULAR ULTRASOUND; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

CORONARY ARTERIOSCLEROSIS; HEART TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 24744471851     PISSN: 0008428X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Hertz MI, Taylor DO, Trulock EP, Boucek MM, Mohacsi PJ, Edwards LB, et al. The registry of the International Society for Heart and Lung Transplantation: nineteenth official report - 2002. J Heart Lung Transplant 2002;21:950-70.
2. Labarrere CA, Nelson DR, Faulk WP. Myocardial fibrin deposits in first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am J Med 1998;105:207-13.
3. Labarrere CA. Anticoagulation factors as predictors of transplant-associated coronary artery disease. J Heart Lung Transplant 2000;19:623-33.
4. Gamba A, Mammana C, Fiocchi R, Iamele L, Mamprin F. Cyclosporine and graft coronary artery disease after heart transplantation. Compr Ther 2000;26:121-6.
5. Aranda JM, Hill J. Cardiac transplant vasculopathy. Chest 2000;118:1792-800.
6. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant 1992;11(3 Pt 2):S38-44.
7. Lozano MD. Microvascular coronary arterial vasculopathy - predictive value of endomyocardial biopsy [review]. Z Kardiol 2000;89 Suppl 9:IX/54-7.
8. Russell ME. Cardiac allograft vasculopathy - a changing perspective. Z Kardiol 2000;89 Suppl 9:LX/6-10.
9. Johnson DE, Gao SZ, Schroeder JS, DeCampli WM, Billingham ME. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Lung Transplant 1989;8:349-59.
10. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol 1988;12:334-40.
11. Hoang K, Chen YD, Reaven G, Zhang L, Ross H, Billingham M, et al. Diabetes and dyslipidemia. A new model for transplant coronary artery disease. Circulation 1998;97:2160-8.
12. Kemna MS, Valantine HA, Hunt SA. Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J 1994;128:68-72.
13. Benza RL, Tallaj J. Cardiac allograft vasculopathy (chronic rejection). In: Kirklin JK, McGiffin DC, editors. Heart transplantation. Philadelphia: Churchill Livingstone; 2002. pp. 615-64.
14. Costanzo-Nordin MR. Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 1992;11(3 Pt 2): S90-103.
15. Esper E, Glagov S, Karp RB, Simonsen KK, Filer SR, Scanu AM, et al. Role of hypercholesterolemia in accelerated transplant coronary vasculopathy: results of surgical therapy with partial ileal bypass in rabbits undergoing heterotopic heart transplantation. J Heart Lung Transplant 1997; 16:420-35.
16. Fodinger M, Wagner OF, Horl WH, Sunder-Plassmann G. Recent insights into the molecular genetics of homocysteine metabolism. Kidney Int 2001;59:S238-42.
17. Fodinger M, Sunder-Plassmann G. Increased cysteine plasma levels in kidney transplants: a potential vascular disease risk factor? Transplantation 2001;71:713-5.
18. Sunder-Plassmann G, Fodinger M. Cost-effectiveness of homocysteine-lowering therapy to prevent coronary heart disease. JAMA 2002;287:190.
19. Stein G, Muller A, Busch M, Fleck C, Sperschneider H. Homocysteine, its metabolites, and B-group vitamins in renal transplant patients. Kidney Int Suppl 2001;78:S262-5.
20. Ambrosi P, Garcon D, Riberi A, Habib G, Barlatier A, Kreitmann B, et al. Association of mild hyperhomocysteinemia with cardiac graft vascular disease. Atherosclerosis 1998;138:347-50.
21. Ambrosi P, Barlatier A, Habib G, Garcon D, Kreitman B, Roland PH, et al. Hyperhomocysteinaemia in heart transplant recipients. Eur Heart J 1994;15:1191-5.
22. Langman LJ, Ray JG, Evrovski J, Yeo E, Cole DE. Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case-control study. Arch Intern Med 2000;160:961-4.
23. Cook RC, Tupper JK, Parker S, Kingsbury K, Frohlich JJ, Abel JG, et al. Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation. J Heart Lung Transplant 1999;18:420-4.
24. Cook RC, Parker S, Kingsbury K, Frohlich JJ, Abel JG, Gao M, et al. Effective treatment of hyperhomocysteinemia in heart transplant recipients with and without renal failure. J Heart Lung Transplant 2001;20:310-5.
25. Cole DE. Homocysteine as a risk factor in cardiovascular disease. Adv Exp Med Biol 2001;498:59-64.
26. Miner SE, Cole DE, Evrovski J, Verma A, Daly PA, Ross HJ. Hyperhomocysteinemia and transplant coronary artery disease in cardiac transplant recipients. Clin Transplant 2001;15:258-62.
27. Miner SE, Cole DE, Evrovski J, Forrest Q, Hutchison S, Holmes K, et al. Pyridoxine improves endothelial function in cardiac transplant recipients. J Heart Lung Transplant 2001;20:964-9.
28. Cole DE, Ross HJ, Evrovski J, Langman LJ, Miner SE, Daly PA, et al. Correlation between total homocysteine and cyclosporine concentrations in cardiac transplant recipients. Clin Chem 1998;44: 2307-12.
29. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338:1042-50.
30. Doshi SN, Goodfellow J, Lewis MJ, McDowell IF. Homocysteine and endothelial function. Cardiovasc Res 1999; 42:578-82.
31. Chambers JC, Ueland PM, Wright M, Dore CJ, Refsum H, Kooner JS. Investigation of relationship between reduced, oxidized and protein-bound homocysteine and vascular endothelial function in healthy human subjects. Circ Res 2001;89:187-92.
32. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012-7.
33. Zhang X, Li H, Jin H, Brodsky S, Goligorsky MS. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol Renal Physiol 2000;279:F671-8.
34. Ambrosi P, Garcon D, Riberi A, Habib G, Barlatier A, Kreitmann B, et al. Association of mild hyperhomocysteinemia with cardiac graft vascular disease. Atherosclerosis 1998;138:347-50.
35. Gupta A, Moustapha A, Jacobsen DW, Goormastic M, Tuzcu EM, Hobbs R, et al. High homocysteine, low folate, and low vitamin B6 concentrations: prevalent risk factors for vascular disease in heart transplant recipients. Transplantation 1998;65: 544-50.
36. Ardehali A, Fischbein MP, Yun J, Irie Y, Fishbein MC, Laks H. Indirect alloreactivity and chronic rejection. Transplantation 2002;73:1805-7.
37. Game DS, Warrens AN, Lechler RL. Rejection mechanisms in transplantation. Wien Klin Wochenschr 2001;113:832-8.
38. Fischbein MP, Yun J, Laks H, Irie Y, Fishbein MC, Espejo M, et al. CD8+ lymphocytes augment chronic rejection in a MHC class II mismatched model. Transplantation 2001;71:1146-53.
39. Szeto WY, Krasinskas AM, Kreisel D, Krupnick AS, Popma SH, Rosengard BR. Depletion of recipient CD4+ but not CD8+ T lymphocytes prevents the development of cardiac allograft vasculopathy. Transplantation 2002;73:1116-22.
40. Costanzo MR, Naftel DC, Pritzker MR, Heilman JK, Boehmer JP, Brozena SC, et al. The Cardiac Transplant Research Database: heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 1998;17:744-53.
41. Faulk WP, Labarrere CA, Pitts D, Halbrook H. Laboratory-clinical correlates of time-associated lesions in the vascular immunopathology of human cardiac allografts. J Heart Lung Transplant 1993;12: S125-34.
42. Mehra MR, Ventura HO, Chambers R, Collins TJ, Ramee SR, Kate MA, et al. Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study. J Am Coll Caraiol 1995; 26:1537-44.
43. Uretsky BF, Murali S, Reddy GS. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporin and prednisone. Circulation 1987;76:244.
44. Schutz A, KemKes BM, Kugler C, Angermann C, Schad N, Rienmuller R, et al. The influence of rejection episodes on the development of coronary artery disease after transplantation. Eur J Cardiothorac Surg 1990;4:300-7.
45. Gohra H, MacDonal TO, Verrier ED, Aziz S. Endothelial loss and regeneration in a model of transplant arteriosclerosis. Transplantation 1995;60:96-102.
46. Boyle EM Jr, Lille ST, Allaire E, Clowes AW, Verrier ED. Endothelial cell injury in cardiovascular surgery: ischemia-reperfusion. Ann Thorac Surg 1996;62:1868-75.
47. Byrne JG, Smith WJ, Murphy MP, Couper GS, Appleyard RF, Cohn LH. Complete prevention of myocardial stunning, contracture, low-reflow, and edema after heart transplantation by blocking neutrophil adhesion molecules during reperfusion. J Thorac Cardiovasc Surg 1992;104:1589-96.
48. Tsao PS, Aoki N, Lefer DJ, Johnson G 3rd, Lefer AM. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat. Circulation 1990;82:1402-12.
49. Tsao PS, Lefer AM. Time course and mechanism of endothelial dysfunction in isolated ischemic and hypoxic perfused rat heart. Am J Physiol 1994;266:HI28-36.
50. Seccombe JF, Schaff HV. Coronary artery endothelial function after myocardial ischemia and reperfusion. Ann Thorac Surg 1995;60:778-88.
51. Bienvenu K, Granger DN. Molecular determinants of shear rate-dependent leukocyte adhesion in postcapillary venules. Am J Physiol 1993;264:H1504-8.
52. Ma XL, Weyrich AS, Lefer DJ, Buerke M, Albertine KH, Kishimoto TK, et al. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ Res 1993;72:403-12.
53. Smith CW, Entman ML, Lane CL, Beaudet AL, Ty TI, Youker K, et al. Adherence of neutrophils to canine cardiac myocytes in vitro is dependent on intercellular adhesion molecule-1. J Clin Invest 1991;88:1216-23.
54. Baldwin WM 3rd, Pruitt SK, Brauer RB, Daha MR, Sanfilippo F. Complement in organ transplantation. Contributions to inflammation, injury and rejection [review]. Transplantation 1995;59:797-808.
55. Day JD, Rayburn BK, Gaudin PB, Baldwin WM 3rd, Lowenstein CJ, Kasper EK, et al. Cardiac allograft vasculopathy: the central pathogenic role of ischemia-induced endothelial cell injury [review]. J Heart Lung Transplant 1995;14(6 pt 2): S142-9.
56. Yamani MH, Haji SA, Starling RC, Tuzcu EM, Ratliff NB, Cook DJ, et al. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome. J Am Coll Cardiol 2002; 39:970-7.
57. Subramanian AK, Quinn TC, Kickler TS, Kasper EK, Tucker PC. Correlation of Chlamydia pneumoniae infection and severity of accelerated graft arteriosclerosis after cardiac transplantation. Transplantation 2002;73:761-4.
58. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561-6.
59. Weis M, Kledal TN, Lin KY, Panchal SN, Gao SZ, Valantine HA, et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation 2004;109:500-5.
60. Botas J, Pinto FJ, Chenzbraun A, Liang D, Schroeder JS, Oesterle SN, et al. Influence of preexistent donor coronary artery disease on the progression of transplant vasculopathy: an intravascular ultrasound study. Circulation 1995;92:1126-32.
61. Takada M, Nadeau KC, Hancock WW, Mackenzie HS, Shaw GD, Waaga AM, et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 1998;65:1533-42.
62. Wilhelm MJ, Pratschke J, Beato F, Taal M, Kusaka M, Hancock WW, et al. Activation of the heart by donor brain death accelerates acute rejection after transplantation. Circulation 2000;102:2426-33.
63. Nissen S. Coronary angiography and intravascular ultrasound. Am J Cardiol 2001;87(4A):15A-20A.
64. Rickenbacher PR, Pinto FJ, Chenzbraun A, Botas J, Lewis NP, Alderman EL, et al. Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol 1995;25:171-7.
65. Schoenhagen P, Nissen S. Understanding coronary artery disease: tomographic imaging with intravascular ultrasound. Heart 2002;88:91-6.
66. Tuzcu EM, Kapadia SR, Tutor E, Ziada KM, Hobbs RE, McCarthy PM, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation 2001;103:2705-10.
67. Mehra MR, Ventura HO, Stapleton DD, Smart FW, Collins TC, Ramee SR. Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant 1995;14:632-9.
68. Spes CH, Angermann CE. Stress echocardiography for assessment of cardiac allograft vasculopathy. Z Kardiol 2000;Suppl 9:IX/50-3.
69. Spes CH, Mudra H, Schnaack SD, Klauss V, Reichle FM, Überfuhr P, et al. Dobutamine stress echocardiography for noninvasive diagnosis of cardiac allograft vasculopathy: a comparison with angiography and intravascular ultrasound. Am J Cardiol 1996;78:168-74.
70. Yuan X, Dong VM, Coito AJ, Waaga AM, Salama AD, Benjamin CD, et al. A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection. Transplantation 2002;73:1736-42.
71. Kevelaitis E, Nyborg NC, Menasche P. Coronary endothelial dysfunction of isolated hearts subjected to prolonged cold storage: patterns and contributing factors. J Heart Lung Transplant 1999;18:239-47.
72. Rao V, Feindel CM, Cohen G, Borger MA, Boylen P, Ross HJ. Is profound hypothermia required for storage of cardiac allograft? J Thorac Cardiovasc Surg 2001;122:501-7.
73. Rao V, Feindel CM, Weisel RD, Boylen P, Cohen G. Donor blood perfusion improves myocardial recovery after heart transplantation. J Heart Lung Transplant 1997;16:667-73.
74. Rao V, Feindel CM, Cohen G, Borger MA, Boylen P, Ross HJ. Effect of metabolic stimulation on cardiac allograft recovery. Ann Thorac Surg 2001;7:219-25.
75. Fedak PW, Rao V, Ramzy D, Verma S, Tumiati LC, Boylen P, et al. Combined endothelial and myocardial protection by endothelin antagonism enhances transplant allograft preservation. J Thorac Cardiovasc Surg 2005;129:407-15.
76. Okada K, Nishida Y, Murakami H, Sugimoto I, Kosaka H, Monta H, et al. Role of endogenous endothelin in the development of graft arteriosclerosis in rat cardiac allografts. Antiproliferative effects of bosentan, a nonselective endothelin receptor antagonist. Circulation 1998;97:2346-51.
77. Yamaguchi A, Miniati DN, Hirata K-I, Hoyt G, Robbins RC. Ex vivo blockade of endothelin-1 inhibits graft coronary artery disease in a rodent cardiac allograft model. J Heart Lung Transplant 2002;21:417-24.
78. Simonson MS, Robinson AV, Schulak JA, Hricik DE. Inhibition of endothelin-1 improves survival and vasculopathy in rat cardiac transplants treated with cyclosporine. Transplantation 2002;73:1054-9.
79. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Kaeppler HA, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847-58.
80. Fellström B. Impact and management of hyperlipidemia posttransplantation. Transplantation 2000;70:SS51-7.
81. Farmer JA. Pleiotropic effects of statins [review]. Curr Atheroscler Rep 2000;2: 208-17.
82. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000; 47:648-57.
83. Li D, Chen HJ, Metha JL. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. Cardiovasc Res 2001;52:130-5.
84. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin in outcomes after cardiac transplantation. N Engl J Med 1995; 333:621-7.
85. Keogh A, Macdonald P, Kaan A, Aboyoun C, Spratt P, Mundy J. Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. J Heart Lung Transplant 2000;19:529-37.
86. Sindermann JR, Fan L, Weigel KA, Troyer D, Muller JG, Schmidt A, et al. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis 2000;150:331-41.
87. Patel DN, Pagani FD, Koelling TM, Dyke DB, Baliga RR, Cody RJ, et al. Safety and efficacy of atorvastatin in heart transplant recipients. J Heart Lung Transplant 2002; 21:204-10.
88. Parisi F, Danesi H, DiCiommo V, Fina F, Giannone G, Colistro F, et al. Treatment of hyperhomocysteinemia in pediatric heart transplant recipients. J Heart Lung Transplant 2003;22:778-83.
89. 12 status in cardiac transplant recipients. J Heart Lung Transplant 2004; 23:405-12.
90. Kutschka I, Pething K, Strüber M, Dieterich C, Harringer W, Haverich A. Homocysteine - a treatable risk factor for allograft vascular disease after heart transplantation? J Heart Lung Transplant 2001;20:743-6.
91. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant 2004;23:S187-93.
92. Vassalli G, Gallino A, Weis M, von Scheidt W, Kappenberger L, von Segesser LK, et al. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 2003;24:1180-8.
93. Kerman RH, Susskind B, Kerman D, Lam M, Gerolami K, William J, et al. Comparison of PRA-STAT, sHLA-EIA, and anti-human globulin-panel reactive antibody to identify alloreactivity in pretransplantation sera of heart transplant recipients: correlation to rejection and posttransplantation coronary artery disease. J Heart Lung Transplant 1998;17:789-94.
94. Orloff MS, DeMara EM, Coppage ML, Leong N, Fallon MA, Sickel J, et al. Prevention of chronic rejection and graft arteriosclerosis by tolerance induction. Transplantation 1995;59:282-8.
95. Madsen JC, Yamada K, Allan JS, Choo JK, Erhorn AE, Pins MR, et al. Transplantation tolerance prevents cardiac allograft vasculopathy in major histocompatibility complex class I-disparate miniature swine. Transplantation 1998;65:304-13.
96. Yamada K, Choo JK, Allan JS, Erhorn AE, Menard MT, Mawulawde K, et al. The effect of thymectomy on tolerance induction and cardiac allograft vasculopathy in a miniature swine heart/kidney transplantation model. Transplantation 1999;68:485-91.
97. Zhang QW, Tomita Y, Matsuzaki G, Shimizu I, Iwai T, Okano S, et al. Heart allograft tolerance without development of posttransplant cardiac allograft vasculopathy in chimerism-based, drug-induced tolerance. Transplantation 2002;73:652-6.
98. Miniati DN, Robbins RC. Heart transplantation: a thirty year perspective. Annu Rev Med 2002;53:189-205.